Because TLRs, especially TLR2 and TLR4, are implicated in the pathogenesis of OC [5, 11], compounds displaying either agonist or antagonist activities may represent a potential immunotherapeutic opportunity for cancer treatment, whether used alone or in combination with other therapies. This evidence concerns the gene TLR2 and cancer.